Clinical Trial Update: Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01) [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating chemotherapy in combination with toripalimab for hormone receptor-positive, HER2-negative breast cancer is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Toripalimab (Toripalimab)
• neoadjuvant chemotherapy

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: HR+/HER2- Breast Cancer | Phase 2 | Status: RECRUITING